Abstract #5569

Ferumoxytol as an Alternative to Gadolinium-based MRI Applications in Patients With and Without Renal Impairment: Acute and Short-term Safety Experience

Kim-Lien Nguyen^1,2, Takegawa Yoshida^1,3, Isidro B Salusky⁴, Peng Hu^1,3, and J. Paul Finn^1,3

¹Diagnostic Cardiovascular Imaging Laboratory, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States, ²Division of Cardiology, David Geffen School of Medicine at UCLA and VA Greater Los Angeles Healthcare System, Los Angeles, CA, United States, ³Department of Radiological Sciences, David Geffen School of Medicine at UCLA, ⁴Department of Pediatric Nephrology, David Geffen School of Medicine at UCLA

Recent concerns about gadolinium deposition in biologic tissues and discontinuation of gadofosveset trisodium have created increased interest in the off-label use of ferumoxytol as an MRI contrast agent. Limited safety data relating to the diagnostic use of ferumoxytol are available. We summarize our safety experience with ferumoxytol as an alternative MRI contrast agent in 285 unique patients (314 injections) with all levels of renal function.

This abstract and the presentation materials are available to members only; a login is required.

Join Here